Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD
Pilot: Insulin Sensitivity/Management in Hyperglycemic Patients in Perioperative Period ESRD/Non-ESRD
This study is for people with diabetes who have either healthy kidneys or who have end stage
 renal disease (ESRD) and are on hemodialysis that are having surgery. This research will help
 increase our knowledge about how having diseased kidneys and being on hemodialysis changes
 how the body responds to insulin. In the time period directly before, during, and after
 surgery, maintenance of blood sugar within normal physiological range is essential. When
 patients come for surgery and have an elevated blood sugar, it is up to each individual
 physician to decide on the right amount of insulin to treat them. Currently, there are many
 different protocols across the country to treat elevated blood sugar; however, there is no
 one specific protocol to treat elevated blood sugar at SUNY Downstate Medical Center at this
 time. In this study, the investigators will evaluate the change in blood sugar following
 insulin administration to determine whether there is a significantly different response
 between ESRD and non-ESRD patients. The results of the study will help develop safer practice
 guidelines to patients with ESRD with an elevated blood sugar while they are having surgery.
The objective of our study is to compare perioperative changes in blood glucose levels
 following insulin administration (Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ)
 for preoperative hyperglycemia (as defined by blood glucose over 150 mg/dL) in diabetic ESRD
 patients on hemodialysis vs. diabetic non-ESRD patients without CKD. The investigators
 hypothesize that diabetic ESRD patients on hemodialysis with preoperative hyperglycemia will
 demonstrate a more rapid decrease in blood glucose following insulin administration compared
 to diabetic non-ESRD patients without CKD.

 The study will take place at SUNY Downstate Medical Center at the University Hospital of
 Brooklyn. Following enrollment of eligible patients, the following data will be collected:
 age, gender, height, weight, BMI, indicated procedure, medical record number, past medical
 history (including liver dysfunction and EtOH abuse), ASA, and initial blood glucose. All
 patient data associated with renal function and dialysis will be obtained and recorded for
 ESRD patients. Relevant kidney function data, such as GFR, will also be obtained, if
 available. The surgical procedures will include but are not limited to the following elective
 surgeries: major abdominal surgery, major GU/GYN surgeries, vascular surgery, renal
 transplantation, neurosurgery, vascular and orthopedic surgery . The investigators expect
 patients in both groups to undergo similar surgical procedures. All medications prescribed to
 the patient will be noted, as will the type of diabetes the patient has, type 1 or type 2. If
 the patient takes insulin or oral diabetic medications, the time and amount of their last
 dose will be recorded. The interval between the last dialysis and insulin testing will not be
 similar and the extent of uremia will not be equivalent among participants.

 All consented patients with hyperglycemia (blood glucose > 150 mg/dL) will be administered an
 IV bolus of Novolin R human insulin based on a sliding scale according to the table below.
 The anesthesiologist that is taking care of the patient for that specific surgery will
 administer the insulin based on the sliding scale, will measure and record blood glucose at
 30 minute intervals, and will be responsible to adjust treatment as per the study's sliding
 scale. Prior to initiating the protocol, the particular anesthesiologist that is responsible
 for the case will be explained exactly how to follow the protocol. He/she will also be given
 a supplemental form with written instructions. He/she will also be given contact information
 for the principle investigator if they should have any questions or issues. The investigators
 developed a dosing protocol based on guidelines in previous studies, determined as safe and
 effective for perioperative hyperglycemic patients. The treatment protocol will be
 administered as follows:

 1. Patients with preoperative blood glucose > 150 and < 200 mg/dL will be given a bolus of
 2 insulin units.

 2. Patients with preoperative blood glucose > 200 and < 250 mg/dL will be given a bolus of
 3 insulin units.

 3. Patients with preoperative blood glucose > 250 and < 350 mg/dL will be given a bolus of
 4 insulin units.

 Point-of-care blood glucose testing will be measured at 30-minute intervals using a
 glucometer (Nova Biomedical, Waltham, MA. USA), and the investigators will adjust treatment
 to maintain a safe glucose window. Plasma insulin levels will not be tested. ESRD patients
 will be administered normal saline and non-ESRD patients will be administered lactate ringers
 during study protocol. Glucose readings collected at each interval will be recorded, as will
 changes in insulin administration. Treatment will be adjusted as per the sliding scale given
 above. For the purpose of the study and statistical analysis, blood glucose sampling will be
 performed 3 times, one as baseline, second after ½ hour after the first dose of IV insulin,
 and the second after 30 additional minutes. Descriptive statistics (mean, standard deviation)
 for each group at each time point will be used to determine the difference between the ESRD
 and non-ESRD groups in the pilot study. Any additional blood glucose estimations will be
 strictly for clinical reasons to treat hyperglycemia and ascertain that no hypoglycemia has
 occurred. For patient safety, the investigators will not give insulin for blood glucose
 levels less than 150 mg/dL, but will continue to monitor blood glucose at 30-minute intervals
 for 2 hours after the last dose of insulin and will not administer insulin if the blood
 glucose levels fall below 150 mg/dL. Regular insulin when given intravenously has a rapid
 onset and a short duration of action; intravenously the half- life of regular insulin is 0.5
 to 1 hour and the peak effect is 0.8 to 2 hours. The investigators will therefore monitor
 blood glucose levels until the expected peak effect of 2 hours where they expect the lowest
 blood glucose levels. Hypoglycemia is highly unlikely in renal patients at discharge. It is
 customary for patients to stay in the PACU for 2 hours post-surgery. During the 2-hour window
 from the patient's last dose of insulin, the patients will be required to remain NPO except
 water.

 If blood glucose drops below 100 mg/dL, a 25 cc bolus of 50% dextrose in water (Hospira Inc.,
 Lake Forest, IL, USA) will be administered and blood glucose will be checked after 15
 minutes. The investigators will give another dextrose bolus if necessary to restore blood
 glucose above 100 mg/dL. Once blood glucose has reached a level above 100 mg/dL, blood
 glucose will continue to be checked every 30 minutes for 2 hours after the last dose of
 insulin given.

 Of note, this treatment protocol is based on standard practice and designed for patient
 safety. If the patient is discharged before 2 hours, the investigators will terminate the
 study at that point. The patients will not be at increased risk of harm as insulin peak
 effect occurs within 30 minutes. With study termination, the patient will return to their
 normal anti-hyperglycemic regimen. No additional patient participation will be required after
 this point. Blood samples collected for glucose readings will be discarded immediately after
 use. Data will be entered into a password protected Microsoft Excel data sheet.

 This will be pilot study to compare the response to insulin in diabetic patients with ESRD
 vs. diabetic patients without renal disease. The investigators will generate insulin response
 curves for each patient, with blood glucose level as a function of time. Then they will
 compute average drop in glucose in the two groups. Using these data the investigators will be
 able to observe the obtained effect size, determine whether it is clinically significant, and
 if so, determine sample size that would be required to obtain statistical significance for a
 larger study analysis. Based on the outcome of the pilot study, they will determine the
 sample size and the analysis plan for the main study.
Inclusion criteria:

 -  Adult patients over 18 years old with diabetes (both sexes) presenting without any
 kidney disease or with ESRD on hemodialysis

 -  Undergoing major elective surgery procedures such as abdominal, pulmonary, GU/GYN,
 vascular, renal, neurologic, and orthopedic surgery

 -  Signed informed consent for the study.

 -  Patients with elevated preoperative blood glucose of a value > 150 mg/dL or < 350
 mg/dL

 -  English-speaking

 -  Baseline chemistry with a potassium at or above 3.5

 Exclusion criteria:

 -  Patients under the age of 18.

 -  Pregnant women. (Pregnant women have altered glucose metabolism; specific insulin
 regimen used for pregnant women)

 -  Patient does not give informed consent for the study.

 -  Patient does not have decisional capacity or a surrogate.

 -  Patient cannot understand or read English.

 -  Patients with a preoperative blood glucose < 150 mg/dL or >350 mg/dL

 -  Patients without diabetes

 -  Patients with kidney disease that are not on hemodialysis

 -  A history of frequent hypoglycemia in the month prior to surgery by history or a
 change in insulin dose for hypoglycemia in the month prior to surgery

 -  Patients taking steroids or patients that will receive steroids during their surgery

 -  Any patients who refuse to remain NPO except water in the two hour window after their
 last insulin dose

 -  Patients scheduled for cardiac, thoracic and emergency surgeries

 -  Patients who have taken or received insulin or oral hypoglycemic agents after 12 am on
 the day of surgery.

 -  Patients have not adhered to the NPO status.